What is the recommended treatment for Campylobacter (C.) jejuni diarrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Campylobacter jejuni Diarrhea

Azithromycin is the preferred first-line treatment for Campylobacter jejuni diarrhea, with a dosing regimen of 1000 mg single dose or 500 mg daily for 3 days, due to its superior efficacy and low resistance rates. 1

First-Line Treatment Options

  • Azithromycin should be used as first-line therapy for C. jejuni infections, especially in regions with high fluoroquinolone resistance, with a clinical cure rate of 96% 1
  • Early treatment with azithromycin within 72 hours of symptom onset is most effective in reducing symptom duration from 50-93 hours to 16-30 hours 2, 1
  • For severe cases or dysentery, azithromycin 1000 mg single dose is recommended 2, 1
  • For less severe cases, azithromycin 500 mg daily for 3 days is appropriate 2, 1

Alternative Treatment Options

  • Fluoroquinolones (ciprofloxacin, levofloxacin) should only be used in areas with known low fluoroquinolone resistance 1
  • Ciprofloxacin dosing: 750 mg single dose or 500 mg twice daily for 3 days 2, 1
  • Levofloxacin dosing: 500 mg single dose or 500 mg daily for 3 days 2, 1
  • Fluoroquinolone resistance among Campylobacter has increased dramatically worldwide, with resistance rates exceeding 90% in Southeast Asia 1, 3

Treatment Considerations

  • Consider local resistance patterns when choosing empiric therapy 1
  • Clinical failure occurs in approximately 33% of patients treated with fluoroquinolones when the isolate is resistant 1
  • Macrolide (azithromycin, erythromycin) resistance remains relatively low at around 4% for travel-related infections 1
  • Rifaximin (200 mg three times daily for 3 days) may be used for non-dysenteric, non-febrile cases, but should not be used with invasive illness 2, 4

Supportive Care

  • Maintain adequate hydration with clear liquids, aiming for 8-10 large glasses daily 2
  • Dietary modifications include avoiding lactose-containing products, alcohol, and high-osmolar supplements 2
  • Consume bland foods such as bananas, rice, applesauce, and toast 2
  • Loperamide may be used as adjunctive therapy with antibiotics to further reduce gastrointestinal symptoms and duration of illness 2, 4
  • Initial dose of loperamide is 4 mg followed by 2 mg after each loose stool, not to exceed 16 mg in a 24-hour period 2

Special Populations

  • Immunocompromised patients should always receive antibiotic treatment, even for mild infections, due to the risk of systemic spread 1
  • Elderly patients may be more susceptible to dehydration and should be monitored closely 5
  • Children under 2 years should not receive loperamide 2

Common Pitfalls to Avoid

  • Using fluoroquinolones empirically without considering local resistance patterns can lead to treatment failure and prolonged illness 1, 6
  • Delaying treatment beyond 72 hours can reduce the effectiveness of antibiotics 1
  • Continuing use of loperamide alone, or in combination with antibiotics, in the face of worsening symptoms or development of dysentery 2
  • Inadequate fluid replacement, particularly in vulnerable populations 5

When to Seek Further Medical Attention

  • Presence of blood in stool or severe abdominal pain requires immediate medical attention 5
  • Signs of significant dehydration, such as decreased urination, dizziness, or dry mouth 5
  • Fever >38.5°C or symptoms persisting beyond 48 hours despite management 5

Most cases of Campylobacter diarrhea are self-limiting, but antibiotics can significantly reduce symptom duration and prevent complications when administered early in the course of illness 1, 7.

References

Guideline

Treatment of Campylobacter Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Azithromycin-Induced Diarrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995

Research

Campylobacter jejuni Infections: update on emerging issues and trends.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.